On September 27, 2023, Hyperfine, Inc. terminated Khan Siddiqui, M.D.?s part-time employment as the Company?s Chief Medical Officer and Chief Strategy Officer, effective September 30, 2023 (Separation Date), following which Dr. Siddiqui will continue to serve as a consultant of the Company. As previously disclosed, on July 17, 2023 the Company and Dr. Siddiqui had previously agreed to reduce Dr. Siddiqui?s work schedule to a 20% part-time employee schedule. On September 30, 2023, the Company entered into a separation agreement (the ?Separation Agreement?) with Dr. Siddiqui, pursuant to which he will transition on the Effective Date from his role as the Company?s Chief Medical Officer and Chief Strategy Officer to a consultant of the Company, including to assist in the transfer of knowledge and to serve in a clinical and medical affairs advisory capacity.